Hikari Power’s ADMA Biologics ADMA Stock Holding History

Hikari Power’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-30,075	Closed	-$34K	–	67
2021 Q3	$34K	Hold	30,075	–	–	﹤0.01%	68
2021 Q2	$48K	Hold	30,075	–	–	﹤0.01%	70
2021 Q1	$53K	Hold	30,075	–	–	0.01%	67
2020 Q4	$59K	Hold	30,075	–	–	0.01%	70
2020 Q3	$72K	Buy	+30,075	New	+$82.5K	0.01%	59

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Hikari Power's ADMA Position: Q4 2021 in Review

Hikari Power sold out of ADMA Biologics (ADMA) in Q4 2021, closing a stake of 30,075 shares — an estimated $34K sold.

Hikari Power first reported a position in ADMA in Q3 2020 and held it in 5 quarters. The position peaked at $72K in Q3 2020. 88 funds tracked by Wall St. Rank hold ADMA as of Q4 2021.

Hikari Power reported no remaining ADMA Biologics position as of Q4 2021 after selling out during the quarter.
Hikari Power sold 30,075 ADMA Biologics shares in Q4 2021, an estimated $34K.
Hikari Power first reported a position in ADMA Biologics in Q3 2020 and held it in 5 quarters.
Hikari Power's ADMA Biologics position peaked at $72K in Q3 2020.
88 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2021.

Based on Hikari Power's 13F filing for Q4 2021, filed 12 Jan 2022.